A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19

[1]  Steve B Jones,et al.  Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, Lancet.

[2]  S. Rose-John,et al.  Interleukin-6: obstacles to targeting a complex cytokine in critical illness , 2021, The Lancet Respiratory Medicine.

[3]  F. Lammert,et al.  Therapeutic Application of Alpha-1 Antitrypsin in COVID-19 , 2021, medRxiv.

[4]  J. Fountain,et al.  Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids , 2021, American journal of respiratory and critical care medicine.

[5]  Yasser B. Ruiz-Blanco,et al.  Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection , 2021, Nature Communications.

[6]  A. Duhamel,et al.  Protease-antiprotease imbalance in patients with severe COVID-19 , 2021, Clinical chemistry and laboratory medicine.

[7]  Y. Mehta,et al.  Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial , 2021, The Lancet Respiratory Medicine.

[8]  Christopher M. Horvat,et al.  Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report , 2021, medRxiv.

[9]  M. Si-Tahar,et al.  Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia , 2021, European Respiratory Journal.

[10]  C. French,et al.  Rapid Translation of COVID-19 Preprint Data into Critical Care Practice , 2020, American journal of respiratory and critical care medicine.

[11]  N. McElvaney,et al.  Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19 , 2020, Journal of Cystic Fibrosis.

[12]  A. Mebazaa,et al.  Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study , 2020, Intensive Care Medicine.

[13]  R. Porcher,et al.  Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[14]  M. Massari,et al.  Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[15]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[16]  Scott J. Garforth,et al.  Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients , 2020, Science Translational Medicine.

[17]  P. Delvenne,et al.  Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19 , 2020, The Journal of experimental medicine.

[18]  P. Saldiva,et al.  SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology , 2020, The Journal of experimental medicine.

[19]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[20]  R. Hotchkiss,et al.  Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections , 2020, JCI insight.

[21]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[22]  N. McElvaney,et al.  Characterization of the Inflammatory Response to Severe COVID-19 Illness , 2020, American journal of respiratory and critical care medicine.

[23]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[24]  H. Maecker,et al.  Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis , 2020, medRxiv.

[25]  F. Martinez,et al.  Severe Covid-19. , 2020, The New England journal of medicine.

[26]  K. Kehn-Hall,et al.  Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2 , 2020, bioRxiv.

[27]  B. Hobbs,et al.  Consequences of Abrupt Cessation of Alpha1-Antitrypsin Replacement Therapy. , 2020, The New England journal of medicine.

[28]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[29]  R. Stockley,et al.  The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial , 2019, American journal of respiratory and critical care medicine.

[30]  Simon A. Jones,et al.  Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer , 2018, Nature Reviews Immunology.

[31]  T. Greulich,et al.  Safety of biweekly α1-antitrypsin treatment in the RAPID programme , 2018, European Respiratory Journal.

[32]  S. Rose-John,et al.  Interleukin-6: designing specific therapeutics for a complex cytokine , 2018, Nature Reviews Drug Discovery.

[33]  M. Henry,et al.  Glycosylation Repurposes Alpha‐1 Antitrypsin for Resolution of Community‐acquired Pneumonia , 2017, American journal of respiratory and critical care medicine.

[34]  S. Rose-John,et al.  The role of IL-6 in host defence against infections: immunobiology and clinical implications , 2017, Nature Reviews Rheumatology.

[35]  S. Rose-John,et al.  Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation , 2017, PLoS biology.

[36]  N. McElvaney.  Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency. , 2016, Annals of the American Thoracic Society.

[37]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[38]  T. Åkerstedt,et al.  Diurnal Variation of Circulating Interleukin-6 in Humans: A Meta-Analysis , 2016, bioRxiv.

[39]  N. McElvaney,et al.  Unusual Acute Sequelae of α1-Antitrypsin Deficiency: A Myriad of Symptoms With One Common Cure. , 2015, Chest.

[40]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[41]  N. McElvaney,et al.  The Circulating Proteinase Inhibitor α-1 Antitrypsin Regulates Neutrophil Degranulation and Autoimmunity , 2014, Science Translational Medicine.

[42]  T. Welte,et al.  Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase , 2013, Proceedings of the National Academy of Sciences.

[43]  B. Prakken,et al.  Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. , 2013, Methods.

[44]  A. von Eckardstein,et al.  Serum levels and genotype distribution of α1-antitrypsin in the general population , 2012, Thorax.

[45]  Julius Sim,et al.  The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. , 2012, Journal of clinical epidemiology.

[46]  C. Moore,et al.  Recommendations for Planning Pilot Studies in Clinical and Translational Research , 2011, Clinical and translational science.

[47]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[48]  M. Henry,et al.  α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. , 2010, The Journal of clinical investigation.

[49]  A. Dirksen,et al.  Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[50]  E. Chan,et al.  α‐1‐Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood , 2009, Journal of leukocyte biology.

[51]  J. Murabito,et al.  Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress: The Framingham Heart Study , 2007, Circulation.

[52]  P Trayhurn,et al.  Signalling role of adipose tissue: adipokines and inflammation in obesity. , 2005, Biochemical Society transactions.

[53]  P. Williamson,et al.  Design and analysis of pilot studies: recommendations for good practice. , 2004, Journal of evaluation in clinical practice.

[54]  Y. Shapira,et al.  Raised interleukin-6 levels in obese patients. , 2000, Obesity research.

[55]  R. Banks.  Measurement of Cytokines in Clinical Samples Using Immunoassays: Problems and Pitfalls , 2000, Critical reviews in clinical laboratory sciences.

[56]  R. Buhl,et al.  Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. , 1998, The European respiratory journal.

[57]  R. Stockley,et al.  Role of inflammation in respiratory tract infections. , 1995, The American journal of medicine.

[58]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[59]  G. Döring.  The role of neutrophil elastase in chronic inflammation. , 1994, American journal of respiratory and critical care medicine.

[60]  B. Millar,et al.  Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-alpha concentrations. , 1992, Journal of immunological methods.

[61]  S. Suter,et al.  High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. , 1992, The American review of respiratory disease.

[62]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[63]  R. Crystal,et al.  Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. , 1987, The New England journal of medicine.

[64]  K. Ohlsson,et al.  Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[65]  R. Crystal,et al.  Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. , 1981, The Journal of clinical investigation.

[66]  A. Fein,et al.  Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome. , 1981, The New England journal of medicine.

[67]  M. Sanak,et al.  Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). , 2017, The Lancet. Respiratory medicine.

[68]  Peter C Gøtzsche,et al.  Alpha1-antitrypsin deficiency. , 2009, The New England journal of medicine.

[69]  N. Porchet,et al.  Evaluation of a new Sebia isoelectrofocusing kit for α1-antitrypsin phenotyping with the Hydrasys® System , 2008, Clinical chemistry and laboratory medicine.

[70]  S. Janciauskiene,et al.  Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. , 2007, The Journal of biological chemistry.

[71]  M. Schluchter,et al.  Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. , 2003, Chest.

[72]  R. Crystal,et al.  Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. , 1991, Lancet.

[73]  R. Crystal,et al.  Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. , 1988, JAMA.